February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Kristina Jankovic: Intratumoral Pembrolizumab and mRNA-2752 for High-Risk DCIS
Jan 21, 2025, 09:58

Kristina Jankovic: Intratumoral Pembrolizumab and mRNA-2752 for High-Risk DCIS

Kristina Jankovic, Medical Oncology Resident at University Clinical Center Nis, posted the following on X:

“Intratumoral pembrolizumab and mRNA-2752 for high-risk DCIS: Phase 1 nonrandomized trial

  • 80% response rate
  • No major systemic toxicities
  • Complete tumor resolution in some cases, possibly reducing surgery

Ongoing studies are needed.”

Kristina Jankovic: Intratumoral Pembrolizumab and mRNA-2752 for High-Risk DCIS